Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice-Reference-Cited by-同舟云学术

Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice

Published:2019-07-25 Issue: Volume:10 Page:
ISSN:1664-042X
Container-title:Frontiers in Physiology
language:
Short-container-title:Front. Physiol.

Author:

Ren Liwei,Cui Qiaoli,Liu Wenjuan,Wang Liqian,Liao Yijing,Feng Ying,Sun Wanwan,Yang Yehong,Zhang Zhaoyun,Jin Tianru,Prud’homme Gerald J.,Zhang Lina,Li Yiming,Leng Ying,Wang Qinghua

Funder

Ministry of Science and Technology

Publisher

Frontiers Media SA

Subject

Physiology (medical),Physiology

Reference57 articles.

1. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.;Baggio;Diabetes Metab. Res. Rev.,2004

2. Insulin as a physiological modulator of glucagon secretion.;Bansal;Am. J. Physiol. Endocrinol. Metab.,2008

3. Delivery of peptides and proteins through the blood-brain barrier.;Bickel;Adv. Drug Deliv. Rev.,2001

4. Body-mass index and mortality in a prospective cohort of U.S. adults.;Calle;N. Engl. J. Med.,1999

5. Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis.;Chen;Mol. Metab.,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new trivalent recombinant protein for type 2 diabetes mellitus with oral delivery potential: design, expression, and experimental validation;Journal of Biomolecular Structure and Dynamics;2024-03-11

2. Study on the Interaction Between C3 Gene Polymorphism and Environment in Patients with Type 2 Diabetes Combined with Coronary Artery Disease;Diabetes, Metabolic Syndrome and Obesity;2024-03

3. The Regulation Role of the Gut-Islets Axis in Diabetes;Diabetes, Metabolic Syndrome and Obesity;2024-03

4. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes;European Journal of Pharmacology;2024-01

5. Exploring a novel long-acting glucagon-like peptide-1 receptor agonist built on the albumin-binding domain and XTEN scaffolds;Heliyon;2024-01